Mechanisms of action of SGLT2 inhibitors and their beneficial effects on the cardiorenal axis
Large clinical studies conducted with sodium-glucose co-transporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes and heart failure with reduced ejection fraction have demonstrated their ability to achieve both cardiac and kidney benefits. Although there is huge evidence on SGLT2i-mediated clinical benefits both in diabetic and non-diabetic patients, the pathophysiological mechanisms underlying their efficacy are still poorly understood. Some favorable mechanisms are likely due to the prompt glycosuric action which is associated with natriuretic effects leading to hemodynamic benefits as well as a reduction in glomerular hyperfiltration and renin-angiotensin-aldosterone system activation. In addition to the renal mechanisms, SGLT2i may play a relevant role in cardiorenal axis protection by improving the cardiomyocyte metabolism, by exerting anti-fibrotic and anti-inflammatory actions, and by increasing cardioprotective adipokine expression. New studies will be needed to better understand the specific molecular mechanisms that mediate the SGLT2i favorable effects in patients suffering diabetes. Our aim is to first discuss about the molecular mechanisms underlying the cardiovascular benefits of SGLT2i in each of the main organs involved in the cardiorenal axis. Furthermore, we update on the most recent clinical trials evaluating the beneficial effects of SGLT2i in treatment of both diabetic and non-diabetic patients suffering heart failure.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:100 |
|---|---|
| Enthalten in: |
Canadian journal of physiology and pharmacology - 100(2022), 2 vom: 16. Feb., Seite 93-106 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gronda, Edoardo [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 24.02.2022 Date Revised 24.02.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1139/cjpp-2021-0399 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336452861 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336452861 | ||
| 003 | DE-627 | ||
| 005 | 20231225232158.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1139/cjpp-2021-0399 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1121.xml |
| 035 | |a (DE-627)NLM336452861 | ||
| 035 | |a (NLM)35112597 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gronda, Edoardo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mechanisms of action of SGLT2 inhibitors and their beneficial effects on the cardiorenal axis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.02.2022 | ||
| 500 | |a Date Revised 24.02.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Large clinical studies conducted with sodium-glucose co-transporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes and heart failure with reduced ejection fraction have demonstrated their ability to achieve both cardiac and kidney benefits. Although there is huge evidence on SGLT2i-mediated clinical benefits both in diabetic and non-diabetic patients, the pathophysiological mechanisms underlying their efficacy are still poorly understood. Some favorable mechanisms are likely due to the prompt glycosuric action which is associated with natriuretic effects leading to hemodynamic benefits as well as a reduction in glomerular hyperfiltration and renin-angiotensin-aldosterone system activation. In addition to the renal mechanisms, SGLT2i may play a relevant role in cardiorenal axis protection by improving the cardiomyocyte metabolism, by exerting anti-fibrotic and anti-inflammatory actions, and by increasing cardioprotective adipokine expression. New studies will be needed to better understand the specific molecular mechanisms that mediate the SGLT2i favorable effects in patients suffering diabetes. Our aim is to first discuss about the molecular mechanisms underlying the cardiovascular benefits of SGLT2i in each of the main organs involved in the cardiorenal axis. Furthermore, we update on the most recent clinical trials evaluating the beneficial effects of SGLT2i in treatment of both diabetic and non-diabetic patients suffering heart failure | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a SGLT2 inhibitors | |
| 650 | 4 | |a diabetes | |
| 650 | 4 | |a diabète | |
| 650 | 4 | |a heart failure | |
| 650 | 4 | |a inhibiteurs du co-transporteur 2 de sodium couplé au glucose | |
| 650 | 4 | |a insuffisance cardiaque | |
| 650 | 4 | |a kidney | |
| 650 | 4 | |a rein | |
| 650 | 7 | |a Adipokines |2 NLM | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a Antifibrotic Agents |2 NLM | |
| 650 | 7 | |a Cardiotonic Agents |2 NLM | |
| 650 | 7 | |a Sodium-Glucose Transporter 2 Inhibitors |2 NLM | |
| 700 | 1 | |a Lopaschuk, Gary D |e verfasserin |4 aut | |
| 700 | 1 | |a Arduini, Arduino |e verfasserin |4 aut | |
| 700 | 1 | |a Santoro, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Benincasa, Giuditta |e verfasserin |4 aut | |
| 700 | 1 | |a Palazzuoli, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Gabrielli, Domenico |e verfasserin |4 aut | |
| 700 | 1 | |a Napoli, Claudio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Canadian journal of physiology and pharmacology |d 1964 |g 100(2022), 2 vom: 16. Feb., Seite 93-106 |w (DE-627)NLM000001635 |x 1205-7541 |7 nnns |
| 773 | 1 | 8 | |g volume:100 |g year:2022 |g number:2 |g day:16 |g month:02 |g pages:93-106 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1139/cjpp-2021-0399 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 100 |j 2022 |e 2 |b 16 |c 02 |h 93-106 | ||